
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
- Japan (Japanese)
-
Change country/language
Old Browser
Looks like you're visiting us from United States.
Would you like to stay on the current country site or be switched to your country?
BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA)
クローン 6F7/BTLA (also known as 6F7) (RUO)

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.




Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

Multicolor flow cytometric analysis of CD272 (BTLA) expression on viable Mouse splenic leucocytes. BALB/c Mouse splenocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) [Cat. No. 553141/553142]. The cells were then stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. No. 553092/561880) and with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA) antibody (Cat. No. 569008/569009; Right Plot) at 0.5 µg /test. BD Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the correlated expression of CD272 (BTLA) [or Ig Isotype control staining] versus CD45R/B220 was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.

ImageTitle~BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA)

ImageTitle~BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA)

ImageTitle~BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA)

ImageTitle~BD Horizon™ BV421 Mouse Anti-Mouse CD272 (BTLA)
Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
推奨アッセイ手順
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
関連製品






The 6F7 monoclonal antibody specifically recognizes CD272 which is also known as B- and T-lymphocyte attenuator (BTLA) and is exclusively expressed on lymphoid cells. CD272 (BTLA) is a type 1 transmembrane glycoprotein that is encoded by Btla (B and T lymphocyte associated). CD272 (BTLA) contains a V-type Ig-like domain in its extracellular region followed by a transmembrane sequence, and a cytoplasmic domain with three tyrosine-based motifs, two immunoreceptor tyrosine-based inhibitory motifs (ITIM) and a Grb-2 recognition consensus sequence. The existence of three distinct BTLA alleles has been reported which encode molecules with different Ig domain structure and expression patterns on lymphoid cell subsets amongst different mouse strains. For example, whereas C57BL/6 and BALB/c mice both variably express CD272 (BTLA) on developing and mature T and B lymphocytes and dendritic cells (DC), C57BL/6 mice, but not BALB/c mice, also express CD272 (BTLA) on NK cells and macrophages. CD272 (BTLA) expression is upregulated by activated T cells including Th1, Th2, and anergic T cells. Herpesvirus entry mediator (HVEM), also known as CD270 and LIGHT-R, has been identified as a ligand for CD272 (BTLA). The crosslinking of CD272 (BTLA) by HVEM inhibits T-cell proliferation and cytokine production. CD272 (BTLA) is structurally like other coinhibitory receptors including CD152/CTLA-4 and CD279/PD-1. Although these coinhibitory receptors and their ligands maintain immunological homeostasis and self-tolerance, they may also serve as immune checkpoint molecules that inhibit adaptive immune responses against tumors and chronic infections.

Development References (7)
-
Crawford A, Wherry EJ. Editorial: Therapeutic potential of targeting BTLA.. J Leukoc Biol. 2009; 86(1):5-8. (Clone-specific). View Reference
-
Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol. 2004; 172(10):5931-5939. (Biology). View Reference
-
Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression and is highly induced in anergic CD4+T cells. J Immunol. 2005; 174(6):3377-3385. (Immunogen: Flow cytometry, Immunoprecipitation, Western blot). View Reference
-
Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T follicular helper cells. Science. 2009; 325(5943):1001-1005. (Biology). View Reference
-
Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005; 6(1):90-98. (Biology). View Reference
-
Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003; 4(7):670-679. (Biology). View Reference
-
Watanabe N, Nakajima H. Coinhibitory molecules in autoimmune diseases. Clin Dev Immunol. 2012; 2012:1-7. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.